Ultrasensitive Detection of CNVs
NuProbe has developed an NGS panel using QASeq technology for the simultaneous and ultrasensitive detection of CNVs, indels, and SNVs in breast cancer. The panel has been tested on reference standards and clinical fresh frozen tissue, PMBCs, FFPE tissue, and cfDNA. Similar assays can be customized to target your biomarker needs. For information on available technology solutions, contact us.
Key Features
Sample Flexibility
Compatible with cfDNA, FFPE tissue, and other biospecimens
Simultaneous Detection
CNV detection of 18 genes and mutation profiling of 14 genes from the same sample
Low Sample Input
Results with as little as 5ng of DNA input
QASeq Assays Portfolio
QASeq HER2+ NGS Panel
Accurately detect SNVs and indels in 14 genes associated with breast cancer and CNVs down to 2.05 ploidy or 5% heterozygous single copy gain in HER2.
Overview
The QASeq HER2+ Panel detects gene mutations across 84 breast cancer hotspots in 14 genes and CNVs in HER2. Using QASeq technology, the QASeq HER2+ Panel accurately quantifies SNVs and indels down to 0.1% VAF and CNVs in HER2 down to 5% single heterozygous copy gain/loss from cfDNA or tumor tissue.
Hotspot Mutations
AKT1, AR, BRAF, BRCA1, BRCA2, EGFR, ERBB2 (HER2), ERBB3, ERBB4, ESR1, KRAS, PIK3CA, PTEN, TP53
CNVs
ERBB2 (HER2)
Key Features
-
- Detect SNVs and indels at 0.1% VAF
- Detect CNVs at 2.05 ploidy
- Compatible with tumor-derived or cell-free DNA
Publication Reference:
Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. Nature Communications. (2022).
